Halozyme appoints COUR Pharma CEO Dannielle Appelhans to board

• Halozyme elected Dannielle Appelhans to its board of directors.
• Appelhans has been CEO of COUR Pharmaceuticals since 2023, leading a Genentech collaboration valued up to $1 billion.
• She previously served as CEO of Rubius Therapeutics.
• Earlier roles included senior operations and supply chain leadership at Novartis Gene Therapies, supporting Zolgensma manufacturing and delivery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608181601PR_NEWS_USPR_____LA28735) on August 18, 2026, and is solely responsible for the information contained therein.